Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Sanofi Ord Shs SNYNF

Healthcare

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood... see more

Add To Watchlist

Recent & Breaking News (OTCPK:SNYNF)

Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection

PR Newswire January 5, 2017

Sanofi Announces Soliqua™ 100/33 Now Available in the U.S.

PR Newswire January 4, 2017

Drug Makers Stocks on Investors' Radar -- Immune Pharma, Sanofi, Biostar Pharma, and Heron Therapeutics

PR Newswire January 3, 2017

Sanofi and Boehringer Ingelheim Confirm Closing of Business Swap on January 1st 2017

Business Wire January 2, 2017

What You Need To Know About Cempra's 2 PDUFA Dates This Week

Benzinga.com December 27, 2016

Reasons To Stay Bullish On Alnylam In The New Year

Benzinga.com December 19, 2016

Who Else Might Johnson & Johnson Seek To Acquire With Actelion Now Out Of Its Crosshairs?

Benzinga.com December 14, 2016

The Market In 5 Minutes: All Eyes On The Fed

Benzinga.com December 14, 2016

What We Know About Trump's Potential Pick To Head The FDA

Benzinga.com December 12, 2016

Scottish Medicines Consortium Approves Sanofi Prostate Cancer Drug

PR Newswire Europe Non Regulatory December 12, 2016

Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA

PR Newswire December 8, 2016

Sanofi Genzyme Announces Start of Phase III Study of Isatuximab for Relapsed and Refractory Multiple Myeloma

Business Wire December 5, 2016

Sanofi and JHL Biotech Announce Strategic Biologics Alliance in China

PR Newswire Asia December 4, 2016

Mymetics Starts Research Project with Sanofi for Influenza Vaccines

PR Newswire December 1, 2016

Drug Makers Stocks on Investors' Radar -- Immune Pharma, Sanofi, Biostar Pharma, and Shire

PR Newswire November 28, 2016

Sanofi Receives FDA Approval of Soliqua™ 100/33 for the Treatment of Adults with Type 2 Diabetes

PR Newswire November 21, 2016

New Survey Finds Men in the U.S. Want to Take Charge of Their Own Health and Wellness

PR Newswire November 17, 2016

Regeneron and Sanofi Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheumatology Annual Meeting

PR Newswire November 16, 2016

Sanofi Presented Full Results of a PK/PD Study Comparing Toujeo® to Insulin Degludec in People With Type 1 Diabetes

PR Newswire Europe Non Regulatory November 11, 2016

Regeneron and Sanofi to Present Data from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016

PR Newswire November 11, 2016